AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
Go back to AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program| AbbVie (NYSE: ABBV) | Delayed: 260.51 +4.09 (1.60%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $256.42 | 52 Week High | $68.12 | |||
| Open | $260.99 | 52 Week Low | $50.71 | |||
| Day High | $262.27 | P/E | 56.51 | |||
| Day Low | $257.79 | EPS | $4.61 | |||
| Volume | 1,827,353 | |||||
| Jennison Natural Resources Fund Class B (NASDAQ: RGNX) | Delayed: 9.41 -0.09 (0.95%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.50 | 52 Week High | $25.00 | |||
| Open | $9.38 | 52 Week Low | $7.07 | |||
| Day High | $9.62 | P/E | N/A | |||
| Day Low | $9.32 | EPS | $0.00 | |||
| Volume | 427,632 | |||||
